130 related articles for article (PubMed ID: 1974517)
1. The l-enantiomer of nebivolol potentiates the blood pressure lowering effect of the d-enantiomer.
Xhonneux R; Wouters L; Reneman RS; Janssen PA
Eur J Pharmacol; 1990 Jun; 181(3):261-5. PubMed ID: 1974517
[TBL] [Abstract][Full Text] [Related]
2. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
3. Effects of the selective beta 1-adrenoceptor antagonist, nebivolol, on cardiovascular parameters in the pithed normotensive rat.
Schneider J; Fruh C; Wilffert B; Peters T
Pharmacology; 1990; 40(1):33-41. PubMed ID: 1970437
[TBL] [Abstract][Full Text] [Related]
4. Effect of nebivolol on beat-to-beat and short-term blood pressure variability in spontaneously hypertensive rats.
Bertera FM; Del Mauro JS; Polizio AH; Chiappetta D; Taira CA; Höcht C
Naunyn Schmiedebergs Arch Pharmacol; 2012 Aug; 385(8):833-43. PubMed ID: 22566167
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of nebivolol.
Janssens WJ
J Pharm Belg; 1992; 47(4):323-7. PubMed ID: 1357130
[TBL] [Abstract][Full Text] [Related]
6. Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.
Stoleru L; Wijns W; van Eyll C; Bouvy T; Van Nueten L; Pouleur H
J Cardiovasc Pharmacol; 1993 Aug; 22(2):183-90. PubMed ID: 7692155
[TBL] [Abstract][Full Text] [Related]
7. Does nebivolol influence serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats?
Górska D; Dudarewicz M; Czarnecka E; Andrzejczak D
Pharmacol Rep; 2010; 62(1):86-94. PubMed ID: 20360618
[TBL] [Abstract][Full Text] [Related]
8. Nebivolol is devoid of intrinsic sympathomimetic activity.
Janssens WJ; Van de Water A; Xhonneux R; Reneman RS; Van Nueten JM; Janssen PA
Eur J Pharmacol; 1989 Jan; 159(1):89-95. PubMed ID: 2565239
[TBL] [Abstract][Full Text] [Related]
9. Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats.
Sacco G; Evangelista S; Criscuoli M; Goso C; Bigioni M; Binaschi M; Manzini S; Maggi CA
Eur J Pharmacol; 2005 Mar; 511(2-3):167-74. PubMed ID: 15792785
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular effects of dl-nebivolol and its enantiomers--a comparison with those of atenolol.
Van de Water A; Xhonneux R; Reneman RS; Janssen PA
Eur J Pharmacol; 1988 Oct; 156(1):95-103. PubMed ID: 3208842
[TBL] [Abstract][Full Text] [Related]
11. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats.
Bertera FM; Del Mauro JS; Lovera V; Chiappetta D; Polizio AH; Taira CA; Höcht C
Hypertens Res; 2014 Mar; 37(3):194-201. PubMed ID: 24132009
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the beta1-selectivity of three beta1-selective beta-blockers.
Nuttall SL; Routledge HC; Kendall MJ
J Clin Pharm Ther; 2003 Jun; 28(3):179-86. PubMed ID: 12795776
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects.
Cheymol G; Woestenborghs R; Snoeck E; Ianucci R; Le Moing JP; Naditch L; Levron JC; Poirier JM
Eur J Clin Pharmacol; 1997; 51(6):493-8. PubMed ID: 9112066
[TBL] [Abstract][Full Text] [Related]
14. Effects of nebivolol stereoisomers on the action of adrenaline on blood pressure, heart rate and blood levels of noradrenaline and DOPEG.
Borges N; Martel F; Branco D; Osswald W
J Auton Pharmacol; 1992 Dec; 12(6):429-35. PubMed ID: 1361931
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of intracerebroventricular injections of (+/-)-nebivolol and its enantiomers--a comparison with those of metoprolol in the rat.
Midol-Monnet M; Davy M; Heimburger M; Beslot F; Cohen Y
J Pharm Pharmacol; 1991 Jul; 43(7):504-9. PubMed ID: 1682465
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Toblli JE; Cao G; Casas G; Mazza ON
Am J Hypertens; 2006 Dec; 19(12):1226-32. PubMed ID: 17161767
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol.
Kuroedov A; Cosentino F; Lüscher TF
Cardiovasc Drug Rev; 2004; 22(3):155-68. PubMed ID: 15492765
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of nebivolol.
Mangrella M; Rossi F; Fici F; Rossi F
Pharmacol Res; 1998 Dec; 38(6):419-31. PubMed ID: 9990650
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological properties of nebivolol in man.
Van Bortel LM; de Hoon JN; Kool MJ; Wijnen JA; Vertommen CI; Van Nueten LG
Eur J Clin Pharmacol; 1997; 51(5):379-84. PubMed ID: 9049578
[TBL] [Abstract][Full Text] [Related]
20. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.
Van Nueten L; De Crée J
Cardiovasc Drugs Ther; 1998 Sep; 12(4):339-44. PubMed ID: 9825177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
